^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    177Lu-LNC1010

    i
    Other names: 177Lu-LNC1010, 177Lu-TATE-EB-01, 177Lu-EB-LM3, 177Lu-Evans blue(EB)-LM3
    Associations

    News

    Trials
    Company:
    Dongcheng Pharma, Xiamen University
    Drug class:
    Beta radiation emitter, SSTR2 modulator
    Related drugs:
    Associations

    News

    Trials
    8ms
    Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study. (PubMed, Acta Pharm Sin B)
    Previous studies have shown that an SSTR2 agonist combined with albumin binding moiety Evans blue (denoted as 177Lu-EB-TATE) is characterized by a higher tumor uptake and residence time in preclinical models and in patients with metastatic NETs. Preliminary PRRT efficacy results showed an 83% disease control rate and a 42% overall response rate after two 177Lu-LNC1010 treatment cycles. These encouraging findings warrant further investigations through multicenter, prospective, and randomized controlled trials.
    P1 data • Preclinical • Journal
    |
    SSTR2 (Somatostatin Receptor 2)
    |
    177Lu-LNC1010 • EBTATE
    9ms
    Evaluation of 177Lu-TATE-EB-01（LNC1010）in SSTR2-positive Tumors (clinicaltrials.gov)
    P1/2, N=30, Completed, The First Affiliated Hospital of Xiamen University | Recruiting --> Completed
    Trial completion
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    177Lu-LNC1010
    1year
    Evaluation of 177Lu-TATE-EB-01（LNC1010）in SSTR2-positive Tumors (clinicaltrials.gov)
    P1/2, N=30, Recruiting, The First Affiliated Hospital of Xiamen University | Phase classification: P1 --> P1/2 | N=20 --> 30
    Phase classification • Enrollment change
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive • SSTR Expression
    |
    177Lu-LNC1010
    over3years
    177Lu-EB-LM3 in Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P1, N=20, Recruiting, The First Affiliated Hospital of Xiamen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive • SSTR Expression
    |
    177Lu-LNC1010
    over3years
    177Lu-EB-LM3 in Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, The First Affiliated Hospital of Xiamen University
    New P1 trial
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive • SSTR Expression
    |
    177Lu-LNC1010